In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20.
JAC-antimicrobial resistance（2023）
摘要
Imipenem/relebactam appears to be a potential treatment option for lower respiratory tract infections caused by piperacillin/tazobactam- and meropenem-resistant NME and in Western Europe.
更多查看译文
关键词
<i>pseudomonas aeruginosa</i>,respiratory tract infections,piperacillin/tazobactam-resistant,lower respiratory tract infections,meropenem-resistant,non-morganellaceae
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要